Multiple Sclerosis

Daniel Vitt, PhD, chief executive officer of Immunic, discussed the dual mechanism of vidofludimus calcium, ongoing phase 3 ENSURE trials in relapsing MS, and phase 2 CALLIPER findings suggesting potential neuroprotective effects in progressive MS.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 5, 2026.

The professor of neurology at the University of Colorado discussed evidence from DISCOMS and other trials on disease-modifying therapy discontinuation in older, stable patients with multiple sclerosis. [WATCH TIME: 8 minutes]

At CMSC 2026, the neuroimmunologist and director at OhioHealth MS Center, discussed results from the phase 3 FENhance 1 and 2 studies, highlighting significant reductions in relapse rates and robust MRI outcomes. [WATCH TIME: 3 minutes]

As the MS community reflects on World MS Day, Alla Wilson, a clinical ambulatory pharmacist at Shields Health Solutions, discusses how integrated specialty pharmacy models can improve treatment access, adherence, and patient-reported outcomes for multiple sclerosis.

The neurologist at Orlando Health discussed findings from an analysis of cladribine tablets in patients aged 50 years and older with relapsing multiple sclerosis presented at CMSC 2026. [WATCH TIME: 7 minutes]

The research neuropsychologist at Mount Sinai Rehabilitation Hospital outlined hallmark patterns of cognitive impairment in multiple sclerosis at the 2026 CMSC Annual Meeting. [WATCH TIME: 6 minutes]

The assistant professor of neurology at NYU Grossman School of Medicine discussed how optical coherence tomography can support the 2024 McDonald Criteria for multiple sclerosis at CMSC 2026.

New data presented at CMSC 2026 suggest ocrelizumab provides comparable relapse and MRI control in pediatric- and young-adult–onset multiple sclerosis, with greater disability improvement observed in pediatric patients.

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed important behind the scenes work nurses carry out in neurology care.

German 3-year real-world data shows ozanimod keeps RRMS relapses low, disability stable, and safety consistent in routine care.

A literature review suggests ferritin may serve as a “dual-edged” biomarker in multiple sclerosis, with elevated levels associated with disease progression and low levels linked to impaired remyelination.

A real-world study presented at CMSC 2026 reported year-1 improvements in treatment satisfaction and disease impact measures in patients with MS treated with ublituximab.

An analysis from the phase 3b ENLIGHTEN study presented at the 2026 CMSC Annual Meeting showed that cognitive performance remained stable during long-term treatment with ozanimod in patients with relapsing multiple sclerosis.

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed the unique role of nurses in neurology, from their perspective working with patients with MS.

William Kilgo, MD, and rising chief resident Ashley Nguyen, MD, discuss the evolving neurology residency Match process, offering guidance on competitiveness, interviews, program fit, and recruitment in the virtual era.

The FDA approval of ocrelizumab for pediatric RRMS expands access to a high-efficacy anti-CD20 therapy for children and adolescents with historically limited treatment options.

Machine learning will only transform clinical neurology if predictive accuracy is matched by usability, transparency, and active physician involvement in the design and implementation of tools that support patient care.

CHMP has recommended tolebrutinib for nonrelapsing SPMS following phase 3 data showing reduced disability progression, supporting its role in targeting CNS-driven inflammation.

Jaime Imitola, MD, FAAN, FANA, professor of neurology and director of the UConn Comprehensive MS Center, discussed validation data on VISIBL-MS and its role in improving early MS recognition.

The approved neurofilament light chain test offers a minimally invasive approach to assessing neuroaxonal damage, with potential to complement MRI in routine multiple sclerosis care.

MOGAD Awareness Month highlights the evolution of myelin oligodendrocyte glycoprotein antibody–associated disease from a once-misclassified condition to a distinct neuroimmunologic disorder.

A small case series published in JAMA Neurology found interstitial lung disease in 9% of long-term ocrelizumab-treated patients, with cases emerging after a mean of 10.5 years of therapy.

A neuroimmunology fellow at the Cleveland Clinic shared her experience attending the 2026 ACTRIMS Forum, specifically focusing on the late-breaking data presented in multiple sclerosis.

The director of the Neurology Residency Program at the Marcus Neuroscience Institute discussed the importance of early recognition of invisible symptoms in comprehensive multiple sclerosis care. [WATCH TIME: 9 minutes]